Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01080222
Other study ID # VX09-222-103
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 2010
Est. completion date November 2013

Study information

Verified date September 2020
Source Vertex Pharmaceuticals Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of combination treatment with VX-222 and telaprevir administered for 12 weeks with and without peginterferon-alfa-2a and/or ribavirin. The subjects enrolled in this study are chronically infected with hepatitis C virus (HCV) genotype 1 and will not have previously received treatment for their HCV infection.

This study will include an Investigational Phase and Extension Phase. These phases will contain a Treatment Period and a Follow-up Period. All subjects will be enrolled in the Investigational Phase of this study. Subjects who fail treatment during the Investigational Phase will have the option to enter the Extension Phase at which point they will be eligible to receive peginterferon alfa-2a and ribavirin for a total of 48 weeks.

Based on an evaluation of on-treatment safety, pharmacokinetic and antiviral data from patients in each arm of the trial, Vertex may elect to enroll up to two additional treatment arms (Treatment Arm E and Treatment Arm F) that will evaluate telaprevir/VX-222-based combination therapy. The components of the treatment regimens of these arms will be selected based on clinical data that emerges from the four initially-studied regimens. If enacted, up to 25 patients are expected to enroll in each additional treatment arm.

If Treatment Arm E or Treatment Arm F is discontinued subjects meeting certain criteria will have the option to enter a telaprevir-containing Rollover Phase. Subjects who do not meet the eligibility criteria to enter the Rollover Phase may elect to enter the Extension Phase.


Recruitment information / eligibility

Status Terminated
Enrollment 152
Est. completion date November 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Males and females of non-childbearing potential

- Genotype 1 chronic hepatitis C

- Laboratory evidence of HCV infection for 6 months

- Histologic evidence of chronic hepatitis C

- Subjects who have a body mass index (BMI) of =35 kg/m² (BMI = weight in kg / height² in meters)

- Treatment Arm E: This arm will enroll only subjects infected with HCV genotype 1b virus

- Treatment Arm F: This arm will enroll only subjects infected with HCV genotype 1a virus

Exclusion Criteria:

- Subjects who have received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C

- Subjects with any contraindications to peginterferon alfa-2a and/or ribavirin

- Subjects with any other cause of significant liver disease in addition to hepatitis C, which may include, but is not limited to malignancy with hepatic involvement, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis (NASH), or primary biliary cirrhosis

- Histologic evidence of hepatic cirrhosis

Study Design


Intervention

Drug:
telaprevir
tablet, 1125-mg, twice daily
VX-222
capsule, 100-mg, twice daily
ribavirin
tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing =75-kg, twice daily
Biological:
peginterferon-alfa-2a
subcutaneous injection, 180-mcg, once weekly
Drug:
VX-222
capsule, 400-mg, twice daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Vertex Pharmaceuticals Incorporated

Countries where clinical trial is conducted

United States,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Tolerability Assessed by adverse events, physical examinations, vital signs, 12 lead electrocardiograms (ECGs), and laboratory assessments (serum chemistry, hematology, and urinalysis) vital signs, 12-lead electrocardiograms (ECGs), and laboratory assessments (clinical chemistry, hematology, and urinalysis) 40 weeks
Secondary Proportion of Subjects Who Achieve a Sustained Viral Response 24 weeks after the completion of the last dose of the assigned study drug treatment regimen
Secondary Undetectable HCV RNA Measurements Time to undetectability
Proportion of subjects who achieve undetectable HCV RNA levels at Week 2, Week 4, Week 8, and Week 12
Proportion of subjects who achieve undetectable HCV RNA levels at Week 2 and Week 8
Proportion of subjects who have undetectable HCV RNA levels at the end of treatment
36 weeks
Secondary Proportion of Subjects Who Have a Viral Breakthrough or Relapse 60 weeks
Secondary Plasma Exposures of VX-222 and Telaprevir 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT01708889 - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction Phase 1
Active, not recruiting NCT00563173 - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients Phase 1/Phase 2
Withdrawn NCT01813266 - Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Completed NCT01121731 - A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C Phase 1/Phase 2
Completed NCT00851890 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Phase 2
Completed NCT04391985 - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients Phase 1/Phase 2
Completed NCT04387539 - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants Phase 1/Phase 2
Completed NCT00770198 - sgp130 in Chronic Human Liver Disease N/A
Completed NCT04382937 - Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection Phase 3
Completed NCT00606528 - FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy N/A
Recruiting NCT00294489 - Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT Phase 3
Withdrawn NCT00255359 - Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers Phase 1
Completed NCT00570336 - Study of CTS-1027 in Hepatitis C Patients Phase 2
Completed NCT02292719 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection Phase 2
Completed NCT04385407 - Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Phase 2
Completed NCT04387526 - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 Phase 2/Phase 3
Completed NCT00215865 - PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy Phase 3